Group items tagged

The collapse of the three trading entities in the Converse Pharma Group (Testerworld Limited, Doncaster Pharmaceuticals Group Limited and Eclipse Generics Limited) (the Group) in May 2022 undoubtedly caused ripples throughout the pharmacy industry. The Group, a major supplier of pharmaceuticals, had a combined turnover over £300m, employed 1,000 staff members and supplied over 4,000 pharmacies throughout the country. The Group is licensed and regulated by the MHRA. At the beginning of 2021, a breach of the MHRA licensing regulations caused a temporary (but prolonged) cessation of trading. The Group was able to secure the ongoing support of its secured creditors during this time, however, when the licenses were subsequently reinstated, they came with restrictions. Unfortunately for the Group, the period of the suspension and the subsequent restrictions over the licences caused a significant reduction in revenue, from which the Group was unable to recover. Ultimately, by May this year, the companies in the Group had exhausted their working capital and had no prospect of raising the funding they required to continue to trade.

The Pharmacy Supervision Practice Group held its second meeting to discuss the future modelling of pharmacy practice. Some of the leading bodies from the community pharmacy sector have joined the group. The members explored themes centred around accountability, delegation and responsibility. The session included a wide-reaching discussion, including what future guidance might look like and the continued patient access to the pharmacist through a comprehensive, accessible and equitable community pharmacy offer. Chair of the group, Dr Michael Twigg, Associate Professor of Primary Care Pharmacy, University of East Anglia, said: "The primary objective of the group is to develop a co-designed and co-produced solution that will not only enhance the patient experience within community pharmacy practice, but that will enable the community pharmacy workforce to maximise role and professional skills. "At its second meeting, the group was unanimous that any changes in the delegation, responsibility and accountability space should be in the patient interest, distil confidence for patients and ensure that community pharmacy remains accessible and equitable."

Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a non-executive board director. With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business. During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to sustainable growth and profitability. The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful acquisition by Perrigo Company plc." David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.

Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social Care (DHSC). This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating Committee. The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount deduction scale will no longer apply from July 2022: Fludrocortisone 50micrograms/5ml oral suspension (Group) Lorazepam 1mg/5ml oral suspension (Group) Lorazepam 500micrograms/5ml oral suspension (Group) Zopiclone 3.75mg/5ml oral solution (Group) Zopiclone 7.5mg/5ml oral solution (Group) GA explore5 oral powder 12.5g sachets HCU explore5 oral powder 12.5g sachets MSUD explore5 oral powder 12.5g sachets TYR explore5 oral powder 12.5g sachets The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.

A group of 21 community pharmacies in the Midlands and Yorkshire will have a new name - Pickfords Pharmacy. The group has been created by combining three independent pharmacy businesses which traded as Mr Pickford's, McGills Pharmacy and D&R Sharp. All pharmacies in the new group will be rebranded over the coming months, with a series of launch events planned by local teams. Speaking after the unveiling of the first branch to receive new signage in Hexthorpe Doncaster, Mimi Lau, Pickfords Pharmacy's chief operating officer, said: "This is a turning point for the group, with all our pharmacies operating under one name with a consistent, contemporary brand. "Initial reaction has been fantastic and very soon the name Pickfords Pharmacy will be widely recognised for the great service we deliver to customers and patients every day." Speaking of the consolidation, Nick Yarrow, the newly appointed group chief executive officer, commented: "Since the enlarged group came together last year, we have been striving to ensure that the best elements of each business have been retained for the benefit of our customers and team members. "This is part of our journey to be more than just a pharmacy - we want to be a trusted source of healthcare services at the heart of each one of the communities we serve".

Paydens Pharmacy Group, one of the first multiple pharmacies to adopt hub and spoke model last year, revealed that the move has resulted in significant time savings in store. Centralising dispensing of repeat prescriptions relieves pressure in pharmacy branches and releases time to deliver revenue generating services, the group said. The group created a hub in Maidstone, Kent, to service its highest dispensing branches. The hub uses Centred Solution's FLOWRx Hub Auto to dispense their original pack repeat prescriptions. The group put in the first FLOWRx Hub production line in spring 2022 and then added in a second line in the autumn as they increased production and moved more stores to the hub and spoke model. The innovative solution interfaces with EMIS PMR, Omnicell's Robotic Dispensing System and Universal Logistics Management software as well as Victoria OS ordering software. The hub operation runs during the day Monday to Friday and produces an average of 33,289 packs per week for just under 9,000 patients, leaving plenty of scope to ramp up. The hub is currently dispensing 79.7% of repeat prescription original packs requested by the group's busiest stores.

Well Pharmacy's parent company, Bestway Group, announced on Wednesday (20 March) that it recorded a five per cent growth in revenues to £4.74 billion for the year ending June 2023, alongside a pre-tax profit of £420.9 million. During the year, the company also completed acquisition of Lexon UK Holdings, a leading pharmaceutical wholesaler serving over 3,000 retail pharmacy customers across the UK and Eire. Furthermore, the Group completed the construction of two cement plants in Pakistan, bringing its total cement manufacturing capacity to 15.3 million tonnes per annum. Sir Anwar Pervez OBE, founder and chairman of Bestway Group, expressed optimism about the new business year and said: "The Group has continued on its growth trajectory in 2023 and we are confident that our businesses will continue to gain share within their respective markets during 2024."

Pharmacy Supervision Practice Group, an organisations from across the community pharmacy sector, who have come together to look into the future "supervision" in community pharmacy, have published their final report. Over the course of nine collaborative and positive workshop-style discussions the Supervision Practice Group aimed to provide recommendations to reframe legislation, regulation and professional standards and guidance to achieve a new vision for community pharmacy. The group have produced a report which makes several recommendations on the subjects of: * the legislation relating to "supervision"; * the temporary absence of the RP from the pharmacy; * delegation; * the preparation and assembly of medicines when the RP is not signed in. The group have provided recommendations on which the Department of and Social Care and the regulators can draft specifically worded revisions to legislation and regulatory standards. These specific legislative and regulatory changes that are proposed by government and regulators will be subject to a full consultation process.

A pharmacy group operating in London and the surrounding areas has said it's cliched a financial deal worth £4.25 million with a major global bank to bolster its mergers and acquisitions activity. Osbon Pharmacy Group said on Monday (19 June) that it would use the multi-million-pound funding package from HSBC UK to also invest in bringing accessible and comprehensive medical services closer to the doorstep of Londoners and people of South East England. The family-run business said the new money will open new position which will include opportunities for pharmacists, pharmacy assistants, pharmacy technicians, dispensers, accounts clerks and delivery drivers, taking the company's total headcount to 185. The group, which currently has 26 pharmacies across London and South East England, was established in 2005. The company offers a range of medicine and prescription services as well as offering customary help and advice. It switched to banking with HSBC UK last year as part of a £6.9M refinance package, which saw the business acquire nine pharmacies and takes the total funding provided by HSBC UK to date to £11.1m.

Are you feeling overwhelmed about the MCAT? You're not alone! The MCAT is a challenging test that can feel daunting for even the best students. But don't worry, this article is here to help. This blog post will discuss six clever strategies that will help you pass the MCAT successfully. Follow these tips and you'll be on your way to achieving your dream score. ENROLL IN A PREP COURSE One of the first things you should do when preparing for the MCAT is to enroll in a prep course. Keep in mind that the right MCAT prep course will provide you with the resources and support you need to succeed. Additionally, it can help to take practice tests under simulated testing conditions. This will help you get used to the format of the test and reduce your anxiety on test day. In choosing a prep course, make sure to pick one that is reputable and has a good track record. You should also make sure that the course is affordable and offers a schedule that fits your needs. If possible, you can also take practice tests that are offered by the course. This way, you can get an idea of the type of questions that will be on the test. JOIN A STUDY GROUP Many people find that studying in a group is more effective than studying alone. When you join a study group, you'll have the opportunity to discuss difficult concepts with your peers. Additionally, you'll be able to hold each other accountable and stay on track with your studies. If you're not sure where to find a study group, ask your friends or classmates if they're interested in forming one. You can also check online forums or look for groups that have already been established.

McKesson UK has announced that it has changed its name to Hallo Healthcare Group. This year, in April, European asset management group Aurelius completed the acquisition of McKesson UK. Over recent years, the company has benefited from the introduction of additional services delivered across its more than 1,300 pharmacies, a growing digital offering and the ability to support the increasing trend of primary care being delivered to patients in their home. On Monday, the company posted on LinkedIn: "Today we have officially changed our name from McKesson UK to Hallo Healthcare Group. This marks our separation from the McKesson Corporation and the start of our exciting new world under Aurelius Group ownership."

The Association of Independent Multiple Pharmacies (AIMp) has appointed David Vanns as its non-executive Chairman following the retirement of its long serving Chair Peter Cattee. Vanns will take up the role from April 2023. Cattee, one of the co-founders of AIMp took up the role as its Chairman in 2000. He is also a non-CCA representative on the PSNC. Despite retiring as chairman Cattee will remain on the AIMp board. Commenting on his retirement Cattee said: "It's been my great good fortune to work with almost all of the owners of pharmacy groups throughout England, Scotland and Wales over the years and many other talented people throughout the sector. It's been during a period of increasing consolidation, something which our own business has reflected, and the original founders and Board members Yakub Patel, Kirit Patel, Steve Williams and David Vanns have all been instrumental in shaping pharmacy negotiations to better reflect the views of our natural constituency - pharmacy group owners. A spokesperson for AIMp said: "We thank Peter for his services and dedication to AIMp throughout the years. Our organisation has grown to be a diverse and dynamic organisation representing and supporting pharmacy groups of all sizes, small and large. Our main identity and what unites us in AIMp, irrespective of the size of the pharmacy group, is being Independents, and we are very proud of our identity. We look forward to continuing our work in representing and supporting our members in the best way possible."

The Pharmacy Supervision Practice Group consisting of members from AIMp, APTUK, CCA, NPA, PDA, PFNI and RPS held its fourth workshop to continue discussions on the future modelling of pharmacy practice. The ideas around 'supervision' shared by the organisation earlier formed the basis of the discussion during the workshop and helped to expand understanding of where there was consensus and disagreement. Examples of ideas explored during the workshop include: the extent to which a pharmacist should supervise the medicines assembly process, the purpose and extent to which a pharmacist might be absent from the pharmacy and how this might affect patient safety as well as the nature of whether fixed rules versus a broad framework were preferable for future practice. Chair of the group, Dr Michael Twigg, Associate Professor of Primary Care Pharmacy, University of East Anglia, said "Once again the sector bodies have come together in a collaborative and positive manner to explore the concept of 'supervision' in the context of current and future community pharmacy practice. This session provided an opportunity to constructively challenge assumptions and viewpoints within the group with the aim of moving the discussion forward." As part of the session, the DHSC, GPhC and PSNI gave an overview of the difference between legislation, regulation and guidance which was helpful to inform the group's thinking. Each of the organisations have been asked to use the conversation to refine the ideas presented in advance of the next workshop.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for antibiotics for the treatment of Group A Strep. "Supplies of antibiotics for the treatment of Group A Strep have seen a surge in demand and may be temporarily in limited supply at certain wholesalers and pharmacies," said DHSC. "Supplies are available with manufacturers, and deliveries into wholesalers and pharmacies are being expedited and are expected in the coming days." If the formulation of antibiotic prescribed is unavailable, DHSC has asked clinicians and local pharmacy teams to consider prescribing an alternative form or strength of the antibiotic where appropriate, ensuring the patient is not intolerant to any of the excipients in the alternative and is counselled on the appropriate dose (and volume) required.

The Royal Pharmaceutical Society (RPS) on Wednesday announced that it is spearheading a new project, which aims to delve into the root causes of the growing challenge of medicines shortages across the United Kingdom and provide solutions to mitigate its impact on patients and pharmacy practice. A newly formed advisory group, chaired by RPS Fellow Dr. Bruce Warner, is set to convene later this month. The group will have experts from primary and secondary care, patient advocacy groups, the pharmaceutical industry, suppliers, regulatory bodies, governmental representatives, and NHS officials. The group aims to formulate a robust report to provide expert thought leadership and support for the wider debate on UK policy. Their work will be informed by a thorough literature review, stakeholder interviews, online RPS member events, and patient stories.

The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable groups will receive their appointments the week after. On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18. The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have already scheduled Covid vaccinations alongside their flu jabs. The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.

Ceuta Group has appointed Michael Yates as chief operating officer (COO). In his new role, he will focus on the exploration of future acquisitions to support the Group's growth plans and ensure it continues to provide innovative services and unlock new opportunities for its clients. Prior to joining Ceuta Group, Yates was associated with Procter & Gamble (P&G) for more than 25 years. His career started in the UK and progressed through senior commercial and managing director roles across Europe, Africa and Asia. During his time at P&G, Yates gained insight and experience in building brands in the UK and globally. He has broad category experience across food & drink as well as health, wellness and personal care, having worked with brands such as Pringles, Sunny Delight, Oral B, Vicks, Head & Shoulders and Pantene. With extensive international experience, Michael brings client-side knowledge and insight of successfully expanding brands and adapting business models for markets across the globe. His appointment bolsters Ceuta Group's leadership structure and will support the Group's growth plans and delivery of superior client service.

Jhoots Group, a West Midlands based independent community pharmacy chain, has unveiled plans to expand its digital services after securing a funding worth £8.23m from HSBC bank. The new money will allow the groups branches to offer a digital platform for customers to request prescriptions online, enabling the implementation of a hub and spoke dispensing system to automate prescription deliveries. The innovation aims to reduce the burden of manual processes on pharmacists, allowing staff to use their time efficiently and support the NHS by offering vaccines and minor ailment medicine services. San Jhooty, chief operating officer at Jhoots Group, said: "When faced with the unprecedented challenges of the pandemic, primary and community services came together to support the community and each other.

When I was asked by fellow independent contractors to join the Review Steering Group (RSG) back in late 2020, I said yes, because I wanted, fundamentally, to look for some ways to improve both LPCs and PSNC. Through my experiences with Greater Manchester LPC I had seen the sorts of changes that LPCs could make and the positive impact that those had on local engagement and in allowing us to do more to support contractors: I wanted to help share what we had learned with the rest of the country. I was pretty sure that the national negotiator could make some positive changes as well. It took longer than I had hoped. And it was a lot harder than I had imagined - not least because of the extent of some of the divisions within our sector - but after 15 months of hard work, I'm pleased with where we have got to, and I believe the 37 changes being proposed will help all contractors. Consensus is not a sexy word. It is not something that fires up our imaginations or that we put on our list of key work objectives for the year. It is also not something that might come naturally to us as independent contractors. But consensus is something that matters. It is the thing that allows us, as a vibrant and diverse group of businesses, to see beyond our differences and to fight together for outcomes that benefit every single one of us. Consensus is also the thing that the RSG has been relentlessly focused on throughout its work, and it's at the heart of what will give our LPCs and PSNC a stronger voice for community pharmacy in the future.

DE Group, one of the UK's leading independent pharmaceutical wholesalers, has gone into administration. Pharmacy Business has learnt that the group was put into administration on Monday (May 9), putting hundreds of jobs at risk and stoking fears of a "sudden shock" to pharmaceutical supply chain. A community pharmacy contractor who has done business with the wholesaler for over 20 years told Pharmacy Business: "I fear for the worst. I don't think there will be enough supply of medicines to cope up with a surge at such a short notice." Bharat Shah, founder and CEO of Sigma Pharmaceuticals, another leading short-line wholesaler, said the news will send shock-waves and have "a massive impact on the market" because DE Group enjoyed a "substantial coverage and market share" in the independent pharmacy sector. "It won't be easy for anyone to take on the extra volume as it could jeopardise their own business," he said, adding that Sigma was actively looking into expanding its own operations in the foreseeable future.